脑转移肺癌患者放疗期间脑脊液游离DNA的预后价值
研究纳入19例非小细胞肺癌脑转移患者,在放疗前、中、后采集脑脊液及11例配对血浆,提取游离DNA行二代测序计算脑脊液肿瘤突变负荷(cTMB),并流式检测外周血T细胞亚群。脑脊液游离DNA检出率高于配对血浆,放疗后脑脊液游离DNA突变丰度下降,但cTMB放疗前后无显著差异。cTMB下降或不可测患者颅内无进展生存期有延长趋势(HR 0.28,95%CI 0.07-1.18,P=0.067)。
要点
- 脑脊液游离DNA检出率高于配对血浆样本。
- 放疗后脑脊液游离DNA突变丰度下降,cTMB放疗前后无显著差异。
- cTMB下降或不可测者颅内无进展生存期有延长趋势(HR 0.28,95%CI 0.07-1.18,P=0.067)。
核心结论
- cTMB可作为非小细胞肺癌脑转移患者的预后生物标志物。
研究设计与样本
- 共纳入19例诊断为非小细胞肺癌伴脑转移的患者。
- 采集19例患者脑脊液及11例配对血浆样本,时间点为放疗前、放疗中及放疗后。
- 提取脑脊液与血浆游离DNA,经二代测序计算脑脊液肿瘤突变负荷(cTMB)。
- 采用流式细胞术检测外周血T细胞亚群频率。
主要发现
- 在配对样本中,脑脊液游离DNA检出率高于血浆。
- 放疗后脑脊液游离DNA突变丰度下降。
- cTMB在放疗前后无显著差异。
- cTMB下降或不可测患者的中位颅内无进展生存期尚未达到,与cTMB稳定或升高患者相比有延长趋势(HR 0.28,95%CI 0.07-1.18,P=0.067)。
- 放疗后外周血CD4+T细胞比例下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During the last decades, radiotherapy (RT) for non-small cell lung cancer (NSCLC) with brain metastases (BM) has been developed. However, the lack of predictive biomarkers for therapeutic responses has limited the precision treatment in NSCLC-BM. PATIENTS AND METHODS: In order to find the predictive biomarkers for RT, we investigated the influence of RT on the cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) and the frequency of T cell subsets of NSCLC patients with BM. A total of 19 patients diagnosed as NSCLC with BM were enrolled. The CSF from 19 patients and matched plasma samples from 11 patients were collected before RT, during RT, and after RT. The cfDNA from CSF and plasma were extracted, and the cerebrospinal fluid tumor mutation burden (cTMB) was calculated after through next-generation sequencing. The frequency of T cell subsets in peripheral blood was using flow cytometry. RESULTS: The detection rate of cfDNA was higher in CSF compared to plasma in the matched samples. The mutation abundance of cfDNA in CSF was decreased after RT. However, no significant difference was observed in cTMB before and after RT. Although the median intracranial progression-free survival (iPFS) has not yet been reached in patients with decreased or undetectable cTMB, there was a trend that these patients possessed longer iPFS compared to those with stable or increased cTMB (HR 0.28, 95% CI 0.07-1.18, P = 0.067). The proportion of CD4+T cells in peripheral blood was decreased after RT. CONCLUSION: Our study indicates that cTMB can serve as a prognostic biomarker in NSCLC patients with BMs.
引用
- Qiao S, Hao Y, Cai L, et al. Prognostic value of cell-free DNA in cerebrospinal fluid from lung cancer patients with brain metastases during radiotherapy. Radiat Oncol. 2023. PMID: 36906568. doi:10.1186/s13014-023-02239-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。